Database : HANSEN Search on : HANSENOSTATICOS [Subject descriptor] References found : 185 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 10

go to page

1 / 185

HANSEN

select to print

Id: 19930 Author: Celik, Onur; Yalcin, Sinasi; Gok, Uzeyir; Yavrucuoglu, Emel; Ozturk, Ahmet; Akyol, Ali. Title: Auditory brain stem evoked potentials in patients with leprosy. Source: Int. J. Lepr;65(2):166-169, Jun. 1997. tab. Abstract: Nineteen, randomly selected male patients with lepromatous leprosy were evaluated electrophysiologically. All of these patients had long-standing disease and were treated with dapsone alone. There were statistically significant differences between the values obtained in this group of leprosy patients compared to 20 age-matched controls in auditory brain stem evoked potentials (ABEP). The findings are consistent with a pathologic process located mainly between the cochlear nucleus and the lateral lemniscus in the auditory brain stem pathways. It should be emphasized that our patients had long-standing disease which was treated with dapsone. ABEP could very well be different in leprosy patients diagnosed early and treated for relatively short periods with multidrug therapy. Brain stem evoked response audiometry may be useful for evaluating the possibility of brain stem involvement in leprosy. (AU)^ien. Descriptors: Hanseníase Virchowiana/diag Hanseníase Virchowiana/quimioter Hansenostáticos/uso terap Location: BR191.1

2 / 185

HANSEN

select to print Texto Completo-en

Id: 19878 Author: Ji, Baohong. Title: Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks. Source: Int. J. Lepr;66(3):391-391, Sept. 1998. . Descriptors: Hanseníase/quimioter Hansenostáticos/admin Hansenostáticos/uso terap Limits: Humanos Masculino Feminino Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3cor03.pdf / en Location: BR191.1

3 / 185

HANSEN

select to print Texto Completo-en

Id: 19833 Author: Jacobson, Robert R. Title: Report of workshop on defining the disease and antibacterial therapy. Source: Int. J. Lepr;66(4):572-573, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hansenostáticos/uso terap Hanseníase/quimioter Hanseníase/prev Mycobacterium leprae/ef drogas Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur01.pdf / en Location: BR191.1

4 / 185

HANSEN

select to print

Id: 18410 Author: Cottini, G. B Title: Contributo allo studio di tre casi di lepra con particolare ricuardo alla bacillemia ?- Source: s.l; s.n; 1933. 29p p. . Descriptors: HANSENIASE/compl HANSENIASE/quimioter HANSENIASE/microbiol HANSENIASE/terap ERITEMA NODOSO/etiol ERITEMA NODOSO/patol ERITEMA MULTIFORME/etiol ERITEMA MULTIFORME/patol SISTEMA NERVOSO PERIFERICO/les SISTEMA NERVOSO PERIFERICO/microbiol SISTEMA NERVOSO PERIFERICO/fisiopatol - HANSENOSTATICOS/uso terap  IODO/uso terap  OURO/uso terap  HELIOTERAPIA  MYCOBACTERIUM LEPRAE/isol  CELULAS SANGUINEAS/citol Limits: HUMANO Location: BR191.1; 01780/s

5 / 185

HANSEN

select to print

Id: 18385 Author: Consigny, Sophie; Bentoucha, Abdelhalim; Bonnafous, Pascale; Grosset, Jacques; Ji, Baohong Title: Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice ..- Source: s.l; s.n; 2000. 3 p. tab. Abstract: Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP. Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slighthy more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae (AU). Descriptors: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/farmacocin HANSENOSTATICOS/uso terap MYCOBACTERIUM LEPRAE TESTES DE SENSIBILIDADE MICROBIANA/métodos DROGAS EM INVESTIGACAO/admin DROGAS EM INVESTIGACAO/anal DROGAS EM INVESTIGACAO/uso terap - BACTERICIDAS  QUIMIOTERAPIA COMBINADA  MYCOBACTERIUM LEPRAE/metab  MYCOBACTERIUM LEPRAE/fisiol  DAPSONA/uso terap  RIFAMPINA/uso terap  CLOFAZIMINA/uso terap  OFLOXACINO/uso terap  MINOCICLINA/uso terap  CLARITROMICINA/uso terap Limits: ESTUDO COMPARATIVO Location: BR191.1; 09311/s

6 / 185

HANSEN

select to print

Id: 18384 Author: Biswas, S; Mondal, K. K Title: Multidrug therapy in leprosy can prevent relapse- a retrospective study ..- Source: s.l; s.n; 2002. 6 p. . Abstract: A retrospective study was done at the Leprosy Control Unit (LCU) in Durgapur of Burdwan district, West Bengal, to determine the relapse rate following multidrug therapy (MDT). A total of 1581 patients (1276 PB and 305 MB) completed MDT regimens during a period of 5 years as per WHO recommendations and National Leprosy Eradication Programme (NLEP) guidelines. The treated patients were kept under surveillance as per NLEP guidelines and searched for relapses. The results of MDT were compared with those of pre-MDT (monotherapy) era at the same centre (total: 405 patients; PB-373, MB-32) andalso with those of the Leprosy Clinic in Gopalpur (only dapsone was given to a total of 189 patients, PB-167, MB-22) Following monotherapy, the relapse rate was 10.06% at the Gopalpur Leprosy Clinic and 12.4% at the Dargapur LCU during the 2 years (PB) and 5 years (MB) of surveillance, whereas following MDT no relapse case was encountered both in PB and MB cases during the surveillance periods recommended by WHO. The results of this study are comparable with those of ohter studies. Though a few studies showed relapses during long-term surveillance beyond the periods recommended by WHO, it is once again established that MDT can prevent relapse in leprosy (AU). Descriptors: HANSENIASE/quimioter HANSENIASE/epidemiol HANSENIASE/prev RECIDIVA/prev - HANSENOSTATICOS/admin  HANSENOSTATICOS/hist  HANSENOSTATICOS/normas  HANSENOSTATICOS/uso terap  CLOFAZIMINA/uso terap  DAPSONA/uso terap  RIFAMPINA/uso terap Limits: ESTUDO COMPARATIVO HUMANO Location: BR191.1; 09310/s

7 / 185

HANSEN

select to print

Id: 18325 Author: Pares, Y Title: La lepre: vers une nouvelle approche thérapeuthique pharmacopée et médicine traditionnelles perspective d'avenir ?- Source: Senegal; s.n; 1980. 12p p. . Descriptors: HANSENIASE/hist HANSENIASE/terap HANSENOSTATICOS/clas HANSENOSTATICOS/hist HANSENOSTATICOS/farmacol - DAPSONA/hist  DAPSONA/uso terap  Aralia  ARSÊNICO/uso terap  ANTIMÔNIO/uso terap Limits: HUMANO Location: BR191.1; 00412/s

8 / 185

HANSEN

select to print

Id: 18281 Author: Hertaing, R. de; Coutejore, J Title: La lepre aujourd'hui: conceptions recentes de la lutte contre la lepre ..- Source: Kangu; s.n; s.d. 40 p. ilus, mapas. Descriptors: HANSENIASE DIMORFA/compl HANSENIASE DIMORFA/diag HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/diag HANSENIASE TUBERCULOIDE/compl HANSENIASE TUBERCULOIDE/diag HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/hist HANSENIASE/imunol HANSENIASE/microbiol HANSENIASE/prev HANSENIASE/terap HANSENIASE/transm HANSENOSTATICOS/admin HANSENOSTATICOS/uso terap HANSENIASE/epidemiol - EDUCACAO EM SAUDE/rec hum  EDUCACAO EM SAUDE/métodos  EDUCACAO EM SAUDE/org  EDUCACAO EM SAUDE/tend Limits: HUMANO Location: BR191.1; 00456/s

9 / 185

HANSEN

select to print

Id: 18280 Author: Ustianowski, Andrew P; Lockwood, Diana N. J Title: Leprosy: current diagnostic and treatment approaches ..- Source: s.l; s.n; 2003. 7 p. . Abstract: PURPOSE OF REVIEW: Leprosy remains an important problem globally and leprosy patients may present to physicians outside leprosy endemic areas. We review the recent biological and clinical advances in leprosy. RECENT FINDINGS: Sequencing the genome has been a major biological advance and will open up new possibilities for research. The three cardinal criteria (anaesthetic skin patches, thickened nerves and acid-fast bacilli in skin smears) have not yet been bettered. Multidrug therapy for leprosy is highly effective with low relapse rates though the optimal duration of therapy for multibacillary patients is unclear. Nerve damage remains a significant problem (in some series only 50% responding to steroid therapy). New treatments for leprosy reactions are needed. Stigma remains a problem but is being combated by patient groups. SUMMARY: Far from being eliminated as a public health problem, leprosy still causes a considerable long-term morbidity in both the developing and developed world. New treatments for leprosy reactions are needed and the optimal length of multidrug therapy required further research. (AU). Descriptors: HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/terap MYCOBACTERIUM LEPRAE/imunol MYCOBACTERIUM LEPRAE/patogen QUIMIOTERAPIA COMBINADA - HANSENOSTATICOS/admin  HANSENOSTATICOS/uso terap  INFECCAO/compl  INFECCAO/etiol  SINDROME DE IMUNODEFICIÊNCIA ADQUIRIDA/compl Limits: HUMANO Location: BR191.1; 00356/s

10 / 185

HANSEN

select to print

Id: 18225 Author: Ebenezer, G. J; Norman, G; Joseph, G. A; Daniel, S; Job, C. K Title: Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India ..- Source: s.l; s.n; 2002. 12 p. tab. Abstract: Out of 265 biopsies of leprosy patients received at the Experimental Pathology Laboratory of Schieffelin Leprosy Research and Training Centre from 1987 to 1997 for evaluating resistant strains of M. leprae, using the mouse footpad technique, 49 showed resistant strains of M leprae to varying concentrations of dapsone, rifampicin and clofazimine. 23 (47%) of these were from a control area. With 369 skin-smear positive multibacillary (MB) patients as the risk group (denominator), 23 (6.23%) were resistant to one or more drugs. 18 (4.88%) had dapsone resistance, 5 (1.36%) were resistant to rifampicin and 9 (2.44%) had resistance to low concentrations of clofazimine (0.0001%). Out of the 23 biopsies with drug resistance from the control area, primary dapsone resistance was seen in 7 (30%) biopsies and secondary dapsone resistance in 11 (48%). Primary rifampicin resistance was seen in 4 (17.4%) patients, secondary rifampicin resistance in 1 (4.35%) and primary clofazimine resistance in 7 (30%). 3 (13%) of the strains showed secondary clofazimine resistance. One biopsy had resistant strains to all the three drugs. In a control area where properly supervised effective multidrug therapy (MDT) was regularly administered over the years, the emergence of drug resistance is negligible. It may not be the case if the content, duration and regularity of the drug regimen were not satisfactory. Aware of the possible shortcomings in mass administration of MDT, it is emphasized that mouse footpad studies on drug resistance should be made available at least in endemic areas where the incidence of the disease has not changed despite good MDT coverage in order to monitor the emergence of drug resistance. Research into molecular biological identification of drug resistant-M.leprae should be intensified. These steps would help to institute timely measures to check the spread of any drug-resistant organisms in the community. (AU). Descriptors: Clofazimina/PD Dapsona/PD Farmacorresistência Bacteriana Farmacorresistência Bacteriana Múltipla Índia Hansenostáticos/*PD Hanseníase/*DT/MI Camundongos Camundongos Endogâmicos CBA Testes de Sensibilidade Microbiana Mycobacterium leprae/*DE Rifampina/PD Limits: HUMANO ANIMAL MASCULINO FEMININO Location: BR191.1; 09179/S

11 / 185

HANSEN

select to print

Id: 18213 Author: Mathew, D; Kishore, B. Nanda ; Shwethadri, G. K; Sukumar; Shetty, N. J Title: An evaluation of clinical and histopathological status in paucibacillary leprosy patients after completion of sixed duration therapy ..- Source: s.l; s.n; 2004. 8 p. tab. Abstract: The presente study was carried out involving 25 patients with paucibacillary leprosy who attended the outpatient department of dermatology of Father Muller's Medical College Hospital during the period January 2001 to March 2002. All the patients were examined clinically and histopathologically at the beginning and at the end of six months of MDT and relevant data recorded. Clinicopathological correlation with histopathological classification before MDT was 72% and 68% at the end of MDT in our study. At the end of treatment 4 (16%) cases were clinically active and 8 (32%) were histopathologically active. The study showed that active cases were siginificantly reduced as a result of MDT, both clinically and histopatologically. The histopathological activity that outlasts MDT may be due to the bacillary fragments that persist; but clincial activity coupled with histopathological activity seen in 2 patients at the end of 6 months of MDT was possibly an indicator of relapse and these patients and similar others need to be follewed up for a longer duration. Is this study, resolution of granuloma and clinical activity after completion of MDT were assessed (AU). Descriptors: HANSENIASE TUBERCULOIDE/compl HANSENIASE TUBERCULOIDE/patol HANSENIASE TUBERCULOIDE/fisiopatol HANSENIASE TUBERCULOIDE/terap RESULTADO DE TRATAMENTO HANSENOSTATICOS/admin HANSENOSTATICOS/farmacol HANSENOSTATICOS/uso terap QUIMIOTERAPIA COMBINADA - HANSENIASE/clas  HANSENIASE/diag  HANSENIASE/terap Limits: HUMANO Location: BR191.1; 08999/s

12 / 185

HANSEN

select to print

Id: 18142 Author: Martin M Fisher; William Mccann; Arthur Michele Title: Foot ulcers in hansens Disease ..- Source: New York; s.n; 1964. 5 p. ilus. Abstract: In this report we present the results of our observations of 2 patients in the New York City area with ulcers on the plantar surface. Our purpose in describing these cases is to emphasize the need to consiuder hansens diase in the diagnosis of ulcers of the foot. We have been able to heal theserefractory ulcers by the use of sodium sulfoxone (Diasone sodium), the specific for hansens disease. A critical evaluation of the newr technics for confirmation of this diagnosis is presented. The awareness of the existence of hansens disease helps to differentiate it from the more common causes of leg and foot ulcers in peripheral vascular diseases. Thus there is a need to evaluate all lower extremity ulcers with specifc diagnostic tests, such as blood sugar for diabetes cryoglobulins for cryoglobulinemia ulcer biopsy for epithelioma and a complete blood count bone marrow biopsy and coombs test for sickle cell anemia cooleys anemia and hemolytic anemia. A careful history and accurate physical examination can usually differentiate a thromboangiitis obliterans ulcer from that of peripheral arteriosclerosis obliterans. Similarly the ulcer of varicose veins is differentiated from that of diabetic neuritis by physival evaluation and the postphlebilitic ulcer is differenbtiated from that of choronic lymphedema by lymphangiography. The following are 2 typical cases of foot ulcers due to hansens disease found in the New York City area. (AU). Descriptors: HANSENIASE/compl HANSENIASE/terap ULCERA DO PE/compl ULCERA DO PE/diag ULCERA DO PE/etiol ULCERA DO PE/terap - HANSENOSTATICOS/uso terap  NEURITE/diag  NEURITE/terap Limits: HUMANO Location: BR191.1; 01142/s

13 / 185

HANSEN

select to print

Id: 18108 Author: Britton, W. J; Lockwood, D. N. J Title: Leprosy ..- Source: s.l; s.n; 2004. 10p p. . Abstract: Leprosy remains an important health problem wordlwide. The disease is caused by a chronic granulomatous infection of the skin and peripheral nerves with Mycobacterium leprae. The clinical range from tuberculoid to lepromatous leprosy is a result of variation in the cellular immune response to the mycobacterium. The resulting impaiment of nerve function causes the disabilities associated with leprosy. This review summarises recent advances in understanding of the biology of leprosy, clinical features of the disease, the current diagnostic criteria, and the new approaches to treatment of the infection and the immune-mediated complications. Supervised multi-drug therapy (MDT) for fixed durations is highly effective for all forms of the disease. The widespread implementation of MDT has been associated with a fall in the prevalence of the leprosy but as yet no reduction in the case-detection rate globally. Thus, leprosy control activities must be maintained for decades to interrupt transmission of infection. Descriptors: HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/epidemiol HANSENIASE/etiol HANSENIASE/hist HANSENIASE/prev HANSENIASE/cirurg - HANSENOSTATICOS  NEURITE/patol  NEURITE/terap  INFECCOES OCULARES/patol  INFECCOES OCULARES/terap Location: BR191.1; 01016/s

14 / 185

HANSEN

select to print

Id: 18103 Author: Desforges, J. F; Thayer, W. W; Dawson, J. P Title: Hemolytic anemia induced by sulfoxone therapy, with investigations into the mechanisms of its production ?- Source: Boston; s.n; 1960. 5p p. ilus. Abstract: A case report is presented of a patient in whom clinical evidence of hemolytic anemia with methemoglobinemia developed upon increasing the dosage of sulfoxone which he was receiving for Hansen's disease. Administration of the drug was withdrawn for six weeks, after which studies were made with the use of radioactive iron to demosntrate the hemolytic effect of sulfoxone. By means of tagging cells of a single age group, it was shown that the suceptibility to hemolysis was related to cell age, and it was only after the red cells had been in the circulation for approximately fifty days that they were subject to the hemolytic effects of this drug. No significant biochemical defect could be demonstrated in the erythrocytes of this patient. However, the decline in activity of glucose-6-phosphate dehydrogenase and glutathione reductase in the aging red cell and the reported sensitivity to this drug of patients with red cell deficiency of glucose-6-phosphate dehydrogenase suggest that the hemolytic mechanism is related to this enzyme system. The case demonstrates that drug-induced hemolytic anemia of this type may occur without demonstrable enzymatic defect of the erythrocytes. The observation that patients appear to compensate for the hemolytic anemia and methemoglobinemia if maintained on this drug may be explained by the fact that the older cells containing less adequate enzyme systems are removed from the circulation and an equilibrium is maintained by increased production of red cells with a shorter age span. Descriptors: HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/sangue HANSENOSTATICOS/uso terap ANEMIA HEMOLITICA/ind quim ANEMIA HEMOLITICA/diag ANEMIA HEMOLITICA/etiol - HANSENIASE/clas  HANSENIASE/compl  HANSENIASE/diag  HANSENIASE/terap Limits: RELATO DE CASO Location: BR191.1; 00720/s

15 / 185

HANSEN

select to print

Id: 18100 Author: Browne, S. G Title: La lèpre: maladie à manifestations diverses et à problèmes multiples ?- Source: s.l; s.n; 1964. 10p p. . Descriptors: HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/epidemiol HANSENIASE/etiol HANSENIASE/imunol - HANSENOSTATICOS/ef rad  HANSENOSTATICOS/uso terap  PRECONCEITO  ISOLAMENTO SOCIAL Limits: HUMANO Location: BR191.1; 00517/s

16 / 185

HANSEN

select to print

Id: 17691 Author: Scollard, D. M; Adams, L. B; Gillis, T. P; Krahenbuhl, J. L; Truman, R. W; Williams, D. L Title: The continuing challenges of leprosy ..- Source: s.l; s.n; 2006. 44 p. ilus, tab. Abstract: Leprosy is best understood as two conjoined diseases. The first is a chronic mycobacterial infection that elicits an extraordinary range of cellular immune responses in humans. The second is a peripheral neuropathy that is initiated by the infection and the accompanying immunological events. The infection is curable but not preventable, and leprosy remains a major global health problem, especially in the developing world, publicity to the contrary notwithstanding. Mycobacterium leprae remains noncultivable, and for over a century leprosy has presented major challenges in the fields of microbiology, pathology, immunology, and genetics; it continues to do so today. This review focuses on recent advances in our understanding of M. leprae and the host response to it, especially concerning molecular identification of M. leprae, knowledge of its genome, transcriptome, and proteome, its mechanisms of microbial resistance, and recognition of strains by variable-number tandem repeat analysis. Advances in experimental models include studies in gene knockout mice and the development of molecular techniques to explore the armadillo model. In clinical studies, notable progress has been made concerning the immunology and immunopathology of leprosy, the genetics of human resistance, mechanisms of nerve injury, and chemotherapy. In nearly all of these areas, however, leprosy remains poorly understood compared to other major bacterial diseases. (AU). Descriptors: Antiinfecciosos/TU Proteínas de Bactérias/ME Vacinas Bacterianas Modelos Animais de Doenças Suscetibilidade à Doença/IM Resistência Bacteriana a Drogas Genes Bacterianos/GE Predisposição Genética para Doença Genoma Bacteriano Imunidade Celular Imunidade Natural/GE Hansenostáticos/PD/TU Hanseníase/*/DI/MI/TH Mycobacterium leprae/*/CH/DE/IP/PH Nervos Periféricos/MI Doenças do Sistema Nervoso Periférico/MI/PA Reação em Cadeia da Polimerase Research Support, N.I.H., Extramural Células de Schwann/IM/MI Limits: HUMANO ANIMAL CAMUNDONGOS SUPPORT, NON-U.S. GOV'T Location: BR191.1; 09365/S

17 / 185

HANSEN

select to print

Id: 17689 Author: Scollard, D. M; Joyce M. P; Gillis, T. P Title: Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases ..- Source: s.l; s.n; 2006. 4 p. ilus. Abstract: Humanized monoclonal antibodies to tumor necrosis factor- alpha are valuable for the treatment of rheumatologic conditions, but they have been associated with the development of serious infections. We report the first 2 cases of leprosy developing after treatment with infliximab. After discontinuation of infliximab, both patients developed type 1 ([quot ]reversal[quot ]) leprosy reactions. (AU). Descriptors: Anticorpos Monoclonais/*AE/IM/TU Anti-Reumáticos/*AE/IM/TU Artrite/*DT Glucocorticóides/TU Hansenostáticos/TU Hanseníase Dimorfa/CI/*ET/MI Fator de Necrose Tumoral alfa/AI Limits: HUMANO MASCULINO FEMININO MEIA-IDADE IDOSO SUPPORT, U.S. GOV'T, NON-P.H.S. Location: BR191.1; 09363/S

18 / 185

HANSEN

select to print Texto Completo-pt

Id: 17602 Author: Dalpino, Dirceu; Magna, Luiz Alberto; Opromolla, Diltor Vladimir Araujo. Title: Atividades da NADH-redutase de metemoglobina em hemolisado e membranas eritrocitarias de pacientes hansenianos sob tratamento sulfonico / NADH-reductase activity of metahemoglobin in hemolisis and eritrocytic membranes of leprosy patients on sulphone treatment Source: Hansen. int;23(1/2):14-26, 1998. tab. Abstract: Nos efetuamos determinaçoes da serie vermelha, dosagem da sulfonemia, dosagem de metemoglobina, contagem de reticulocitos e dosagem da atividade enzimatica da NADH-diaforese no hemolisado e nas membranas dos eritrocitos livres de hemoglobina em 72 pacientes portadores de hanseniase, todos ingerindo doses diarias de 100 mg de diaminodifenil-sulfona. Identicos, testes, exceto dosagem de sulfona, foram efetuados no sangue de 72 pessoas normais, na ingerindo medicamentos oxidantes. Foram encontradoas diferenças estatisticas significativas na variaves da serie vermelha, metemoglobina, reticulocitos e na atividade enzimatica da NADH-redutase nas membranas eritrocitarias entre os dois grupos. A atividade enzimatica nas membranas eritrocitarias foi inferior e estatisticamente significativa com relaçao ao grupo-controle...(AU). Descriptors: HANSENIASE/sangue HANSENIASE/quimioter HANSENOSTATICOS Electronic Medium: http://hansen.bvs.ilsl.br/textoc/hansenint/v21aov29/1998/PDF/v23n1-2a02.pdf / pt Location: BR191.1

19 / 185

HANSEN

select to print

Id: 17557 Author: Lockwood, Diana N. J; Suneetha, Sujai Title: Leprosy: too complex a disease for a simple elimination paradigm ..- Source: s.l; s.n; Mar. 2005. 6 p. graf. Abstract: Can leprosy be eliminated? This paper considers the question against the background of the WHO programme to eliminate leprosy. In 1991 the World Health Assembly set a target of eliminating leprosy as a public health problem by 2000. Elimination was defined as reaching a prevalence of < 1 case per 10 000 people. The elimination programme has been successful in delivering highly effective antibiotic therapy worldwide. However, despite this advance, new-case detection rates remain stable in countries with the highest rates of endemic leprosy, such as Brazil and India. This suggests that infection has not been adequately controlled by antibiotics alone. Leprosy is perhaps more appropriately classed as a chronic stable disease than as an acute infectious disease responsive to elimination strategies. In many countries activities to control and treat leprosy are being integrated into the general health-care system. This reduces the stigma associated with leprosy. However, leprosy causes long-term immunological complications, disability and deformity. The health-care activities of treating and preventing disabilities need to be provided in an integrated setting. Detecting new cases and monitoring disability caused by leprosy will be a challenge. One solution is to implement long-term surveillance in selected countries with the highest rates of endemic disease so that an accurate estimate of the burden of leprosy can be determined. It is also critical that broad-based research into this challenging disease continues until the problems are truly solved. (AU). Descriptors: Controle de Doenças Transmissíveis/*OG Prestação Integrada de Cuidados de Saúde/*OG Hansenostáticos/*TU Hanseníase/DI/EP/*PC Mycobacterium leprae Vigilância da População Prevalência Desenvolvimento de Programas/* Saúde Mundial/* Organização Mundial da Saúde/* Limits: HUMANO Location: BR191.1; 09336/s

20 / 185

HANSEN

select to print

Id: 17556 Author: Gill, A. L; Bell, D. R; Gill, G. V; Wyatt, G. B; Beeching, N. J Title: Leprosy in Britain: 50 years experience in Liverpool ..- Source: s.l; s.n; Jun. 2005. 7 p. tab, graf. Abstract: BACKGROUND: Leprosy is a chronic infection that presents with varying dermal and neurological symptoms, and which can lead to extensive disability and morbidity, often with accompanying social stigma. AIM: To review the patients presenting to the Liverpool School of Tropical Medicine (LSTM) between 1946 and 2003, looking specifically at country of birth and of infection, details of clinical presentation, diagnosis, management and reactions. DESIGN: Retrospective record review. METHODS: We retrieved all available clinical records for patients seen between 1946 and 2003 (n = 50), consisting of letters, hospital and LSTM casenotes, and some radiographs and photographs. Any history of tuberculosis or diabetes was recorded. RESULTS: Most patients (64%) were born in the Indian subcontinent, and most were thought to have contracted the disease there (62%). Features at presentation included anaesthetic skin lesions in 19 (36%), hypopigmentation in 15 (30%), and peripheral nerve enlargement in 25 (50%). Diagnoses were made by a combination of clinical data and biopsy (60%), and slit skin smears were positive for acid-fast bacilli in 61% of multibacillary patients. Initial presentation was with a leprosy reaction in five cases (10%), and reactions were documented in 42% of all patients. Treatments were varied, progressing from traditional Eastern medicine to the WHO-approved multidrug therapy in use today, with prophylaxis for children and close contacts. DISCUSSION: Leprosy remains an important diagnosis to consider in patients with a history of work or travel in the tropics, and is a diagnosis with far-reaching medical, social and emotional consequences. (AU). Descriptors: Inglaterra/EP Índia/EH Hansenostáticos/TU Hanseníase/DI/DT/*EP Estudos Retrospectivos Dermatopatias Bacterianas/DI/EP/PA Limits: Adolescente Adulto Idoso Criança Feminino Humanos Masculino Meia-Idade Location: BR191.1; 09335/s

---

page 1 de 10

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information